You are here: Industry Insights > Pfizer

News List

Pfizer Confirms Neuroscience Cuts, Shelves Another 4 Early-Stage Projects biospace
January 31, 2018
Pharma giant Pfizer started January with news it was abandoning research and development of new neuroscience programs that included potential therapies for Alzheimer’s and Parkinson’s.
J&J Bows Out of Race for Pfizer's $20B Consumer Health Biz biospace
January 29, 2018
Late in 2017, Johnson & Johnson indicated it was interested in selling its consumer health business. Several companies, including Johnson & Johnson, GlaxoSmithKline and Reckitt Benckiser have been interested, according to insiders
Johnson & Johnson drops out of the race for Pfizer consumer unit, paving the way for GSK, Reckitt fiercepharma
January 26, 2018
Johnson & Johnson discloses 4Q financial status.
Pfizer's Biosimilar of Biogen, Roche's Rituxan Meets Main Goal in Study biospace
January 25, 2018
Pfizer today announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera®(rituximab-EU), met its primary endpoint. PF-05280586 is being developed by Pfizer as a potential biosimilar to Rituxan®/MabThera®1.
Top 3 Takeover Targets for Pfizer biospace
January 24, 2018
The year is already off to a good start with mergers and acquisitions in the biopharma industry. Celgene Corporation acquired Juno Therapeutics for $9 billion yesterday, and Sanofi bought Biogen spinoff Bioverativ for $11.6 billion.
GlaxoSmithKline is Eyeing Pfizer's $15B+ Consumer Biz biospace
January 11, 2018
GlaxoSmithKline Chief Executive Officer Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.
Why Pfizer Could and Should Make Another Move on Allergan biospace
January 10, 2018
Should Pfizer make another play at acquiring Allergan? At least one analyst thinks the move would be a good one for the pharma giant.
Pfizer to redistribute research funding biospectrumasia
January 09, 2018
Pfizer is expected to eliminate 300 positions from the neuroscience discovery and early development programs.
Pfizer to Cut 300 Jobs as It Ends Alzheimer's, Parkinson's Quest biospace
January 09, 2018
Pfizer announced Saturday, Jan. 6, that it was abandoning research and development into new neuroscience development, including Alzheimer’s and Parkinson’s disease.
Pfizer makes $830m drug discovery pact with Arvinas pharmafile
January 05, 2018
Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing agreement.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page